Diabetes News

Abstract
The American Heart Association's 2017 Scientific Sessions took place in November 2017 in Anaheim, CA, USA. Dr Kenneth Mahaffey (Stanford University, CA, USA) discussed a subgroup analysis1 of the Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS) trial,2 suggesting consistent heart failure and renal benefits to the sodium/glucose cotransporter 2 (SGLT‐2) inhibitor Invokana (canagliflozin) across primary and secondary prevention cohorts.

Source: Journal of Diabetes - December 1, 2017 Category: Endocrinology Authors: Ann M. Carracher, Payal H. Marathe, Kelly L. Close Tags: News Source Type: research